ROLE OF PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9) BEYOND LDLR TARGETING: FOCUS ON GLUCOSE METABOLISM

被引：0
|
作者：
Balzarotti, Gloria [1 ]
Tibolla, Gianpaolo [1 ]
Ruscica, Massimiliano [1 ]
Di Cairano, Eliana [1 ]
Perego, Carla [1 ]
Catapano, Alberico Luigi [1 ,3 ]
Norata, Giuseppe Danilo [1 ,2 ]
机构：
[1] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy
[2] Bassini Hosp, Sisa Ctr, Milan, Italy
[3] Irccs Multimed, Milan, Italy
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.332
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG204
引用
收藏
页码：E102 / E102
页数：1
相关论文
共 50 条
  • [21] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients
    Torino, Claudia
    Carbone, Federico
    Pizzini, Patrizia
    Mezzatesta, Sabrina
    D'Arrigo, Graziella
    Gori, Mercedes
    Liberale, Luca
    Moriero, Margherita
    Michelauz, Cristina
    Fre, Federica
    Isoppo, Simone
    Gavoci, Aurora
    La Rosa, Federica
    Scuricini, Alessandro
    Tirandi, Amedeo
    Ramoni, Davide
    Mallamaci, Francesca
    Tripepi, Giovanni
    Montecucco, Fabrizio
    Zoccali, Carmine
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (09)
  • [22] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
    O'Connell, Emma M.
    Lohoff, Falk W.
    FRONTIERS IN NEUROSCIENCE, 2020, 14
  • [23] Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis
    Lu, Xinjie
    CURRENT DRUG TARGETS, 2019, 20 (10) : 1029 - 1040
  • [24] Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum
    Jabor, Antonin
    Vackova, Tereza
    Kubicek, Zdenek
    Komrskova, Jitka
    Protus, Marek
    Franekova, Janka
    CLINICA CHIMICA ACTA, 2021, 521 : 59 - 63
  • [25] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [26] Proprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
    Bhattacharya, Anindita
    Chowdhury, Abhirup
    Chaudhury, Koel
    Shukla, Praphulla Chandra
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (01):
  • [27] Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel psoriasis susceptibility locus
    Merleev, A.
    Toussi, A.
    Downing, L.
    Tran, M.
    Nava, J.
    Le, S.
    Marusina, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S1 - S1
  • [28] Involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in aortic valvular calcification
    Poggio, P.
    Songia, P.
    Chiesa, M.
    Barbieri, S.
    Moschetta, D.
    Valerio, V.
    Cavallotti, L.
    Ferri, N.
    Zanotti, I.
    Camera, M.
    EUROPEAN HEART JOURNAL, 2018, 39 : 1057 - 1057
  • [29] The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
    Grobelna, Malwina K.
    Strauss, Ewa
    Krasinski, Zbigniew
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA-POLISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2019, 16 (03) : 128 - 132
  • [30] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Affects Gene Expression Pathways Beyond Cholesterol Metabolism in Liver Cells
    Lan, Hong
    Pang, Ling
    Smith, Marsha M.
    Levitan, Diane
    Ding, Wei
    Liu, Li
    Shan, Lixin
    Shah, Vidhi V.
    Laverty, Maureen
    Arreaza, Gladys
    Zhang, Qing
    Murgolo, Nicholas J.
    Hernandez, Marco
    Greene, Jonathan R.
    Gustafson, Eric L.
    Bayne, Marvin L.
    Davis, Harry R.
    Hedrick, Joseph A.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2010, 224 (01) : 273 - 281
12345